Yu Eun-mi, Jain Maneesh, Aragon-Ching Jeanny B
Division of Hematology and Oncology, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue, NW, Washington, DC 20037, USA.
Discov Med. 2010 Dec;10(55):521-30.
Limited treatment options exist for metastatic castrate-resistant prostate cancer (mCRPC). The concept of targeting tumors via anti-angiogenic mechanisms has been studied over the last decade, giving rise to a new class of anti-cancer drugs. Currently, the use of angiogenesis inhibition in prostate cancer is the focus of many ongoing clinical trials, with tumor progression and overall survival established as outcome measures. Several anti-angiogenic agents are currently under investigation with varying mechanisms by which they exert activity against prostate tumors. We describe the significant findings and outcomes of clinical trials involving the use of these drugs in mCRPC patients, along with how these results will translate to their use in the clinical setting. Open interventional trials that are currently recruiting participants are also mentioned. While the use of angiogenesis inhibition holds promise in the treatment of prostate cancer, several challenges still exist. The foreseeable clinical implications and limitations of anti-angiogenic therapy and the potential use of biomarkers are hereby discussed.
转移性去势抵抗性前列腺癌（mCRPC）的治疗选择有限。在过去十年中，通过抗血管生成机制靶向肿瘤的概念得到了研究，催生了一类新的抗癌药物。目前，前列腺癌中血管生成抑制的应用是许多正在进行的临床试验的重点，肿瘤进展和总生存期被确立为疗效指标。目前有几种抗血管生成药物正在研究中，它们对前列腺肿瘤发挥作用的机制各不相同。我们描述了在mCRPC患者中使用这些药物的临床试验的重要发现和结果，以及这些结果将如何转化为其在临床环境中的应用。还提到了目前正在招募参与者的开放介入试验。虽然血管生成抑制在前列腺癌治疗中具有前景，但仍存在一些挑战。在此讨论了抗血管生成治疗可预见的临床意义和局限性以及生物标志物的潜在用途。
